United States Biotechnology & Medical Research

Atea Pharmaceuticals Inc (AVIR)

Track

Track

Atea Pharmaceuticals Inc. experienced insider trading activity most recently on May 18, 2025, when Polly A. Murphy executed a purchase. Prior to this, various executives and affiliates engaged in multiple sell transactions throughout 2024. These historical movements reflect diverse individual portfolio adjustments rather than a singular trend across the leadership team.
Ticker: AVIR Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Atea Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.8
Murphy Polly A. Non-Executive Director
Transaction date
Purchase
Price
67.02
Quantity 76,003 +21.8%
Value US$1,332,460
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Sale
Price
345.80
Quantity 28,351 +37.3%
Value US$3,417,050
2.3
Franklin Berger Lead Independent Director Non-Executive Director
Transaction date
Proposed sale
Price
310.65
Quantity 57,426
Value US$680,021
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.00
Quantity 1,841
Value US$7,367
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.00
Quantity 1,841 -0.0%
Value US$7,367
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.03
Quantity 22,187 -0.4%
Value US$89,469
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.03
Quantity 22,187
Value US$89,469
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.05
Quantity 33,941 -0.6%
Value US$137,318
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.05
Quantity 33,941
Value US$137,318
0.8
Polsky Bruce Non-Executive Director
Transaction date
Sale
Price
3.49
Quantity 17,544 -21.1%
Value US$61,144
0.8
Polsky Bruce Director Non-Executive Director
Transaction date
Proposed sale
Price
3.92
Quantity 17,544
Value US$68,772
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.00
Quantity 1,006 -0.0%
Value US$4,024
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.00
Quantity 1,006
Value US$4,024
Hammond Janet MJ Chief Development Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 14,029 -28.4%
Value US$53,913
Horga Maria Arantxa Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 15,870 -38.2%
Value US$60,963
Foster Wayne EVP, Chief Accounting Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 12,477 -37.4%
Value US$47,904
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Planned sale
Price
3.85
Quantity 56,910 -32.8%
Value US$218,819
Corcoran Andrea See Remarks Officer
Transaction date
Planned sale
Price
3.84
Quantity 15,843 -2.3%
Value US$60,915
Vavricka John Chief Commercial Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 11,819 -35.5%
Value US$45,420
Wayne Foster EVP, Chief Accounting Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 14,311
Value US$58,246
3.7
Jean-Pierre Sommadossi President, CEO, and Chairman
Transaction date
Proposed sale
Price
4.07
Quantity 65,476
Value US$266,487
Janet MJ Hammond Chief Development Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 16,110
Value US$65,568
John Vavricka Chief Commercial Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 13,552
Value US$55,157
Maria Arantxa Horga Chief Medical Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 18,227
Value US$74,184
Andrea Corcoran CFO, EVP, Legal and Secretary
Transaction date
Proposed sale
Price
4.07
Quantity 18,198
Value US$74,066
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Sale
Price
5.16
Quantity 16,166 -2.0%
Value US$83,352
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Sale
Price
5.15
Quantity 25,500 -3.1%
Value US$131,333
1.8
Murphy Polly A. Non-Executive Director
Transaction date
Purchase
Price
8.57
Quantity 12,000 +106.2%
Value US$102,796
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Purchase
Price
24.00
Quantity 41,666 +5.4%
Value US$999,984
3.3
Hack Andrew A. F. Non-Executive Director
Transaction date
Purchase
Price
24.00
Quantity 250,000 +4.7%
Value US$6,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-20 2025-05-18 B Purchase
1.8
Murphy Polly A.
Non-Executive Director
76,003 +21.8%
67.02
US$1,332,460 		76,003 +21.8% 67.02 US$1,332,460
2024-12-12 2024-12-10 S Sale
2.3
BERGER FRANKLIN M
Non-Executive Director
28,351 +37.3%
345.80
US$3,417,050 		28,351 +37.3% 345.80 US$3,417,050
2024-12-10 2024-12-10 PrS Proposed sale
2.3
Franklin Berger

Lead Independent Director

Non-Executive Director
57,426
310.65
US$680,021 		57,426 310.65 US$680,021
2024-09-19 2024-09-19 PrS Proposed sale
JPM Partners LLC

Affiliate
1,841
4.00
US$7,367 		1,841 4.00 US$7,367
2024-09-19 2024-09-19 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
1,841 -0.0%
4.00
US$7,367 		1,841 -0.0% 4.00 US$7,367
2024-09-19 2024-09-18 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
22,187 -0.4%
4.03
US$89,469 		22,187 -0.4% 4.03 US$89,469
2024-09-18 2024-09-18 PrS Proposed sale
JPM Partners LLC

Affiliate
22,187
4.03
US$89,469 		22,187 4.03 US$89,469
2024-09-19 2024-09-17 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
33,941 -0.6%
4.05
US$137,318 		33,941 -0.6% 4.05 US$137,318
2024-09-17 2024-09-17 PrS Proposed sale
JPM Partners LLC

Affiliate
33,941
4.05
US$137,318 		33,941 4.05 US$137,318
2024-06-21 2024-06-20 S Sale
0.8
Polsky Bruce
Non-Executive Director
17,544 -21.1%
3.49
US$61,144 		17,544 -21.1% 3.49 US$61,144
2024-06-20 2024-06-20 PrS Proposed sale
0.8
Polsky Bruce

Director

Non-Executive Director
17,544
3.92
US$68,772 		17,544 3.92 US$68,772
2024-06-07 2024-06-05 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
1,006 -0.0%
4.00
US$4,024 		1,006 -0.0% 4.00 US$4,024
2024-06-05 2024-06-05 PrS Proposed sale
JPM Partners LLC

Affiliate
1,006
4.00
US$4,024 		1,006 4.00 US$4,024
2024-02-02 2024-02-01 PlS Planned sale
Hammond Janet MJ

Chief Development Officer

Officer
14,029 -28.4%
3.84
US$53,913 		14,029 -28.4% 3.84 US$53,913
2024-02-02 2024-02-01 PlS Planned sale
Horga Maria Arantxa

Chief Medical Officer

Officer
15,870 -38.2%
3.84
US$60,963 		15,870 -38.2% 3.84 US$60,963
2024-02-02 2024-02-01 PlS Planned sale
Foster Wayne

EVP, Chief Accounting Officer

Officer
12,477 -37.4%
3.84
US$47,904 		12,477 -37.4% 3.84 US$47,904
2024-02-02 2024-02-01 PlS Planned sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
56,910 -32.8%
3.85
US$218,819 		56,910 -32.8% 3.85 US$218,819
2024-02-02 2024-02-01 PlS Planned sale
Corcoran Andrea

See Remarks

Officer
15,843 -2.3%
3.84
US$60,915 		15,843 -2.3% 3.84 US$60,915
2024-02-02 2024-02-01 PlS Planned sale
Vavricka John

Chief Commercial Officer

Officer
11,819 -35.5%
3.84
US$45,420 		11,819 -35.5% 3.84 US$45,420
2024-02-01 2024-02-01 PrS Proposed sale
Wayne Foster

EVP, Chief Accounting Officer

Officer
14,311
4.07
US$58,246 		14,311 4.07 US$58,246
2024-02-01 2024-02-01 PrS Proposed sale
3.7
Jean-Pierre Sommadossi

President, CEO, and Chairman
65,476
4.07
US$266,487 		65,476 4.07 US$266,487
2024-02-01 2024-02-01 PrS Proposed sale
Janet MJ Hammond

Chief Development Officer

Officer
16,110
4.07
US$65,568 		16,110 4.07 US$65,568
2024-02-01 2024-02-01 PrS Proposed sale
John Vavricka

Chief Commercial Officer

Officer
13,552
4.07
US$55,157 		13,552 4.07 US$55,157
2024-02-01 2024-02-01 PrS Proposed sale
Maria Arantxa Horga

Chief Medical Officer

Officer
18,227
4.07
US$74,184 		18,227 4.07 US$74,184
2024-02-01 2024-02-01 PrS Proposed sale
Andrea Corcoran

CFO, EVP, Legal and Secretary
18,198
4.07
US$74,066 		18,198 4.07 US$74,066
2022-11-15 2022-11-14 S Sale
2.3
BERGER FRANKLIN M
Non-Executive Director
16,166 -2.0%
5.16
US$83,352 		16,166 -2.0% 5.16 US$83,352
2022-11-15 2022-11-11 S Sale
2.3
BERGER FRANKLIN M
Non-Executive Director
25,500 -3.1%
5.15
US$131,333 		25,500 -3.1% 5.15 US$131,333
2021-12-21 2021-12-20 B Purchase
1.8
Murphy Polly A.
Non-Executive Director
12,000 +106.2%
8.57
US$102,796 		12,000 +106.2% 8.57 US$102,796
2020-11-04 2020-11-03 B Purchase
2.8
Rock Springs Capital Management LP
Large shareholder
7,292 +2.6%
24.00
US$175,008 		7,292 +2.6% 24.00 US$175,008
2020-11-04 2020-11-03 B Purchase
2.8
Rock Springs Capital Management LP
Large shareholder
242,708 +17.2%
24.00
US$5,824,992 		242,708 +17.2% 24.00 US$5,824,992
2020-11-03 2020-11-03 B Purchase
2.3
BERGER FRANKLIN M
Non-Executive Director
41,666 +5.4%
24.00
US$999,984 		41,666 +5.4% 24.00 US$999,984
2020-11-03 2020-11-03 B Purchase
3.3
Hack Andrew A. F.
Non-Executive Director
250,000 +4.7%
24.00
US$6,000,000 		250,000 +4.7% 24.00 US$6,000,000
Explore more

More insider trading research around Atea Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America